Clinical Trials Browser

Phase 2 × Fibrosis × durvalumab × Clear all

NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Terminated

8 enrolled 9 charts

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal